Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cytheris SA
Issy-les-Moulineaux, Francecytheris.com ↗
- Ownership
- Private
- Employees
- ~33
- Development stage
- Other
01
Overview
Clinical trials conducted on more than 240 patients demonstrated the ability of CYT107 to expand and protect CD4+ and CD8+ T-cells in various pathologic conditions with a consistent safety and tolerability profile. In HIV patients, a Phase I/II study showed that after 48 weeks, patients treated at the higher dose level had a median increase in CD4+ and CD8+ T-cell counts of 75% and 57%, respectively, from baseline levels.
- Therapeutic areas
- OncologyImmunologyHematologyNeurologyInfectious Diseases
- Modalities
- Recombinant human Interleukin-7 (r-hIL-7, CYT107)
- Industry
- Biotech
Beyond the preview
Go deeper on Cytheris SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytheris SA.